研究業績（原著と症例報告のみ） 2012年

原著
1．Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: A randomized trial.
Furusyo N, Ogawa E, Sudoh M, Murata M, Ihara T, Hayashi T, Ikezaki H, Hiramine S, Mukae H, Toyoda K, Taniai H, Okada K, Kainuma M, Hayashi J.
Journal of Hepatology (2012) 57: 1186-1192.

2．A hypertriglyceridemic state increases high sensitivity C-reactiveprotein of Japanese men with normal glucose tolerance.
Okada K, Furusyo N, Murata M, Sawayama Y, Kainuma M, Hayashi J.
Endocrine (2012) 41: 96-102.

3．Association between chronic hepatitis C virus infection and high levels of circulating N-terminal pro-brain natriuretic peptide.
Okada K, Furusyo N, Ogawa E, Ikezaki H, Ihara T, Hayashi T, Kainuma M, Murata M,
Hayashi J.
Endocrine (2012) 43: 200-5.

4．Pegylated interferon alpha-2b plus ribavirin for Japanese chronic hepatitis C patients with
normal alanine aminotransferase.
Kainuma M, Furusyo N, Azuma K, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T,
Maruyama T, Nakamuta M, Kotoh K, Shimoda S, Hayashi J: The Kyushu University Liver Disease Study Group.
Hepatology Research (2012) 42: 33-41.

5．Evaluation of the adverse effect of premature discontinuation of pegylated interferon alpha-2b and ribavirin treatment for chronic hepatitis C virus infection: Results from Kyushu University Liver Disease Study (KULDS).
Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; The Kyushu University Liver Disease Study (KULDS) Group.
Journal of Gastroenterology and Hepatology (2012) 27: 1233-1240.

6．Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.
Ogawa E, Furusyo N, Murata M, Ikezaki H, Ihara T, Hayashi T, Toyoda K, Taniai H, Okada K, Kainuma M, Hayashi J.
Journal of Hepatology (2012) 57: 534-540.

7．An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin.
Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; The Kyushu University Liver Disease Study (KULDS) Group.
Journal of Infection and Chemotherapy (2012) 18: 689-697.

8．Serum pepsinogen and Helicobacter pylori infection-a Japanese population study.
Toyoda K, Furusyo N, Ihara T, Ikezaki H, Urita Y, Hayashi J.
European Journal of Clinical Microbiology and Infectious Disease (2012) 31: 2117-2124.

9．The utility of visceral fat level by bioelectrical impedance analysis in the screening of metabolic syndrome: The results of the Kyushu and Okinawa Population Study (KOPS).
Unno M, Furusyo N, Mukae H, Koga T, Eiraku K, Hayashi J.
Journal of Atherosclerosis and Thrombosis (2012) 19: 458-466.

10．Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia of Egyptian hepatitis C virus patients.
Ahmed WH, Furusyo N, Zaky S, El Din AS, Alam HA, Ogawa E, Murata M, Hayashi J.
World Journal of Gastroenterology (2012) 19: 1387-95.

11．Vigorous cleaning and adequate ventilation are necessary to control an outbreak in a neonatal intensive care unit.
Shimono N, Hayashi J, Matsumoto H, Miyake N, Uchida Y, Shimoda S, Furusyo N, Akashi K.
Journal of Infection and Chemotherapy (2012) 18: 303-307.

12．Laparoscopic splenectomy with IFN therapy in one hundred HCV-cirrhotic patients with hypersplenism and thrombocytopenia.
Akahoshi T, Tomikawa M, Kawanaka H, Furusyo N, Kinjo N, Tsutsumi N, Nagao Y, Hayashi J, Hashizume M, Maehara Y.
Journal of Gastroenterology and Hepatology (2012) 27: 286-290.

13．Effect of laparoscopic splenectomy in patients with Hepatitis C and cirrhosis carrying IL28B minor genotype.
Motomura T, Shirabe K, Furusyo N, Yoshizumi T, Ikegami T, Soejima Y, Akahoshi T, Tomikawa M, Fukuhara T, Hayashi J, Maehara Y.
BMC Gastroenterology (2012) 12: 158.



症例報告
1．骨髄不全症候群を基礎とした輸血歴のない続発性ヘモクロマトーシスの1例
池崎裕昭、古庄憲浩、大田黒滋、居原毅、小川栄一、豊田一弘、谷合啓明、貝沼茂三郎、岡田享子、村田昌之、澤山泰典、林純
臨牀と研究 (2012) 89: 94-98.

2. インターフェロン先行投与後の抗レトロウイルス療法により免疫再構築症候群の発症なくHBs抗原の陰性化が得られたHBV/HIV重複感染の1例
光本富士子、村田昌之、池崎裕昭、小川栄一、谷合啓明、豊田一弘、大田黒　滋、貝沼茂三郎、岡田享子、古庄憲浩、林　純
感染症学雑誌 (2012) 86: 763-767.

3．免疫再構築症候群が契機となり副腎クリーゼを発症したAIDSの1例
平峯　智、村田昌之、酒見倫子、大西八郎、小川栄一、谷合啓明、長崎洋司、古庄憲弘、林　純
日本内科学会雑誌 (2012) 101: 1389-1392.

4．早期のART導入が奏功したHIV合併重症化B型急性肝炎（genotype A）の1例
平峯　智、村田昌之、大西八郎、小川栄一、谷合啓明、古庄憲浩、林　純
日本病院総合診療学会雑誌 (2012) 3: 76-80.


＜研究分野・研究実績トップへ戻る

ページの先頭へ移動する